Skip to main content
. Author manuscript; available in PMC: 2014 Feb 13.
Published in final edited form as: J Clin Pharmacol. 2013 Jun 15;53(7):699–710. doi: 10.1002/jcph.92

Table 3.

PK Parameters

Age Groups (N)

0–2 (3) 3–5 (10) 6–11 (7) 12–17 (4) Adult (53)

Description Parameter Units Mean (CV%)
Formulation-dependent parameters
  Absorption rate constant (NaPBA) KA1 1/h 1.34 (56) 1.45 (40) 1.88 (39) 1.8 (33) 1.43 (51)
  Absorption rate constant (GPB) KA2 1/h 0.31 (48) 0.42 (24) 0.44 (39) 0.3 (53) 0.35 (54)
  PBA % metabolized presystemically (NaPBA) Alpha/(1 + alpha) × 100 % 3 (25) 4 (15) 6 (17) 9 (19) 10 (17)
  PBA % metabolized presystemically (GPB) Alpha/(1 + alpha) × 100 % 8 (24) 12 (14) 17 (15) 24 (16) 27 (14)
  PAA % metabolized to PAGN presystemically (NaPBA) Beta/(1 + beta) × 100 % 100 100 100 100 100
  PAA % metabolized to PAGN presystemically (GPB) Beta/(1 + beta) × 100 % 53 (13) 63 (6) 72 (5) 79 (4) 82 (3)
PBA
  Clearance for PBA CLB L/h 3.5 (23) 5.9 (31) 6.6 (27) 11.8 (23) 13.6 (38)
  Volume of distribution for PBA VPB L 3.6 (39) 6.2 (100) 9.2 (99) 9.2 (40) 14.7 (52)
PAA
  Vmax for PAA to PAGN conversion VMPA µmol/h 1368 (26) 2092 (16) 3166 (18) 4697 (21) 5559 (19)
  Km for PAA to PAGN conversion KMPA µM 193 193 193 193 193
  Clearance for PAA calculated as Vmax/Km (linear portion) L/h 7.1 10.9 16.4 24.4 28.9
  Volume of Distribution for PAA VPA L 6.6 (44) 12.8 (35) 15.7 (38) 57.6 (85) 47.2 (71)
PAGN
  Clearance for PAGN CLG L/h 3 (23) 5 (22) 7.7 (12) 12.7 (18) 11.9 (25)
  Volume of distribution for PAGN VPG L 6.1 (26) 8.7 (20) 18.7 (46) 20.9 (18) 24.6 (24)

Note: Km is the same for all age groups because no variability parameter (BSV) was estimated for KMPA.